14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
ADXN vs PYPD
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ADXN vs PYPD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PYPD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)
PYPD Overall Winner
6-Pillar Tally: ADXN 1 – 4 PYPD (1 Tie)
Matrix Metrics: ADXN 1 – 6 PYPD
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADXN carries a Unified Composite Score of 30.2/100 (SELL) at $3.57 (N/M Forward P/E, -3130.7% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both ADXN (30.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
ADXN
NASDAQ
Addex Therapeutics Ltd American Depositary Shares
Pharmaceutical Preparations
Market Cap
$7.1M
TTM Revenue
$83,069
Forward P/E
N/M
Beta / 30D Vol
2.28β · 307% Vol
Unified Composite Score
30.2 / 100
SELL
Tech 3.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.7 · SMA20: $3.21 · SMA50: $3.21
PYPD
NASDAQ
Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
Market Cap
$132.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.88β · 59% Vol
Unified Composite Score
31.1 / 100
SELL
Tech 50.0
Fund 27.0
Flow 56.0
Mom 32.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40
6-Pillar Scorecard Institutional Category Breakdown (ADXN 1 – 4 PYPD)
Columns: Metric · ADXN · PYPD
1. Valuation Multiples
ADXN
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
85.7x
N/M
2. Growth & Scale
PYPD
Revenue Growth (YoY)
-72.7%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$83,069
N/A
Market Cap
$7.1M
$132.2M
3. Profitability & Quality
PYPD
Gross Margin
N/A
N/A
Operating Margin
-3130.7%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-150.6%
-243.6%
4. Balance Sheet & Cash Flow
PYPD
Cash Generation (TTM)
-$2.6M EBITDA
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$2.18 Book/Sh · -150.6% ROE
$5.0M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PYPD
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
N/A (N/A)
106.3% (12th %ile)
Put/Call OI Skew
Thin ADR Chain
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ADXN (1) vs PYPD (6)
Institutional Metric
ADXN
PYPD
Criterion
Row Edge
Market Capitalization
Scale
$7.1M
$132.2M
Larger Scale
PYPD
Trailing P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
-72.7%
+0.0%
Higher Growth
PYPD
Operating Margin (TTM)
Profitability
-3130.7%
0.0%
Higher Margin
PYPD
Net Profit Margin
Profitability
0.0%
0.0%
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
-150.6%
-243.6%
Higher ROE
ADXN
52-Week Range Position
Momentum
11% ($3–$12)
82% ($4–$7)
Stronger Trend
PYPD
Beta / 30D Volatility
Risk Regime
2.28β · 307% Vol
0.88β · 59% Vol
Lower Realized Risk
PYPD
Unified Institutional Score
Composite Signal
30.2 / 100 (SELL)
31.1 / 100 (SELL)
Higher Composite
PYPD
Trailing 12M Revenue (USD)
Operating Scale
$83,069
N/A
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
N/A
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 85.7x EV/Rev
N/M PEG · N/M EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.6M EBITDA ($2.18 Book/Sh · -150.6% ROE)
N/A ($5.0M Net Cash)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
PYPD +8.28 pp
ADXN:
+29.35%
·
PYPD:
+37.63%
3M Horizon
PYPD +76.19 pp
ADXN:
-40.0%
·
PYPD:
+36.19%
6M Horizon
PYPD +83.93 pp
ADXN:
-46.88%
·
PYPD:
+37.05%
1Y Horizon
PYPD +138.8 pp
ADXN:
-57.85%
·
PYPD:
+80.95%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADXN vs PYPD. Trailing 12-month operating profitability (ADXN -3130.7% vs PYPD 0.0%) and valuation multiples (ADXN N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
ADXN ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $83,069
Gross Margin N/A
Op. Margin -3130.7%
ROE / Fwd P/E -150.6% · N/M
PYPD ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin 0.0%
ROE / Fwd P/E -243.6% · N/M
ADXN
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
Thin ADR Chain
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
PYPD
BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV
106.3%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
ADXN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1M market capitalization and -3130.7% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PYPD Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ADXN vs PYPD Key Questions & Quantitative Answers
Is ADXN or PYPD a better stock to buy right now?
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADXN carries a Unified Composite Score of 30.2/100 (SELL) at $3.57 (N/M Forward P/E, -3130.7% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.50 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both ADXN (30.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Does ADXN or PYPD have stronger revenue and earnings growth?
PYPD leads the Growth & Scale pillar: ADXN posts -72.7% YoY revenue growth and +0.0% YoY earnings growth on $83,069 TTM revenue (N/A gross margin, -3130.7% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADXN generates $83,069 in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, ADXN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.
Is ADXN or PYPD cheaper on valuation?
ADXN screens cheaper on headline valuation multiples. ADXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.7x EV/Revenue (unreported EBITDA margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADXN (-150.6% ROE) versus PYPD (-243.6% ROE) capital efficiency.
How is options market volatility positioned on ADXN vs PYPD?
In options market volatility and institutional positioning, ADXN carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.28β · 307% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).
Addex Therapeutics Ltd American Depositary Shares (ADXN) Research Suite
PolyPid Ltd. Ordinary Shares (PYPD) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.